Issued Jinyang Pharm’s No. 1 convertible bonds of 16 billion won (R&D financing) November 2021
Signed a joint clinical research contract for 'choline alfoscerate formulation'
Signed a phase 1 clinical research contract for 'anti-diabetic drug combination (JY302)'
A contract for 'Anti-diabetic drug combination (JY302) development '
Acquired ISO37001 December 2019
Signed an 'Esomeprazole formulation technology' export contract with ATHENA of France
Acquired health functional food distribution specialized sales business
Signed a joint clinical research contract for 'Streptokinase and Streptodornase formulations'
Issuance of a certificate of conformity to pharmaceutical manufacturing and quality control standards of Wonju GMP factory
Completed qualification evaluation of Wonju GMP factory
Acquired import/sales business such as imported food
Approved use of Wonju GMP factory
Judgement of conformity to pharmaceutical manufacturing and quality control standards of Wonju GMP factory
Started construction of Wonju GMP factory
"Signed a co-promotion contract for "antihypertensive combination* 'IMPRIDA®' with Sandoz Korea * Angiotension II Receptor Antagonists + Calcium Channel Blockers Combination"
Jinyang Pharm Co., Ltd. signed an Imprida joint marketing contract with Sandoz Korea
2000s
Established Seoul Research Center of Jinyang Pharm Co., Ltd. June 2009
Acquired KGSP Qualified Business Certification
Acquired medical device import business license
Acquired health functional food import business license and sales business license
Taxpayer's Day: Commendation from the Deputy Prime Minister January 2006
European and US patents for leukemia treatment method: Removal of Ascorbate in Plasma (US06989143 / EP01278536)
Participated in Seoul National University College of Pharmacy-Nanobio drug development project
Completed Seocho-dong head office building
Signed a joint service contract with Samsung Seoul Hospital for molecular biology research and clinical research of leukemia drugs
Selected as an excellent technology company (Korea Technology Credit Guarantee Fund)
